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This study describes the development of a new questionnaire to measure health-related
quality of life (HRQoL) in patients with type 1 diabetes (the ViDa1 questionnaire) and
provides information on its psychometric properties. For its development, open interviews
with patients took place and topics relevant to patients’ HRQoL were identified and
items were generated. Qualitative analysis of items, expert review, and refinement of
the questionnaire followed. A pilot study (N = 150) was conducted to explore the
underlying structure of the 40-item ViDa1 questionnaire. A Principal Component Analysis
(PCA) was performed and six of the items that did not load on any of the factors were
eliminated. The results supported a four-dimensional structure for ViDa1, the dimensions
being Interference of diabetes in everyday life, Self-care, Well-being, and Worry about
the disease. Subsequently, the PCA was repeated in a larger sample (N = 578) with
the reduced 34-item version of the questionnaire, and a Confirmatory Factor Analysis
(CFA) was performed (N = 428). Overall fit indices obtained presented adequate
values which supported the four-factor model initially proposed [(χ2(df =554) = 2601.93)
(p < 0.001); Root Mean Square Error of Approximation = 0.060 (CI = 0.056 −0.064)].
As regards reliability, the four dimensions of the ViDa1 demonstrated good internal
consistency, with Cronbach’s alphas ranging between 0.71 and 0.86. Evidence of
convergent-discriminant validity in the form of high correlations with another specific
HRQoL questionnaire for diabetes and low correlations with other constructs such as
self-efficacy, anxiety, and depression were presented. The ViDa1 also discriminated
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between different aspects of clinical interest such as type of insulin treatment, presence
of chronic complications, and glycemic control, temporal stability, and sensitivity to
change after an intervention. In conclusion, the ViDa1 questionnaire presents adequate
psychometric properties and may represent a good alternative for the evaluation of
HRQoL in type 1 diabetes.
Keywords: health-related quality of life, type 1 diabetes, questionnaire, validation, patients, patient-reported
outcome, patient centered research
INTRODUCTION
Type 1 diabetes is a chronic disease caused by autoimmune
destruction of the beta cells in the pancreas, leading to an absolute
insulin deficit. People with type 1 diabetes need to inject insulin
in order to survive (Atkinson et al., 2014).
The discovery of insulin in 1921 represented a decisive
breakthrough in the prognosis of type 1 diabetes, which had
previously been a fatal disease. The publication of the results of
the Diabetes Control and Complications Trial (DCCT) in the
early 1990s was another milestone in the management of type
1 diabetes; intensive treatment with multiple (3–6) injections
or a continuous subcutaneous insulin infusion pump in order
to reach near normal concentrations of blood glucose was
shown to reduce the development of chronic complications
and to improve disease control (DCCT Research Group, 1993).
Thereafter, intensive insulin therapy became the standard of care
in type 1 diabetes.
In addition to the administration of insulin, intensive
treatment also requires the frequent measurement of glucose in
capillary blood and adjustment of the insulin dose depending
on glucose levels, intake, and planned physical activity (DCCT
Research Group, 1993). The management of type 1 diabetes
is complex and requires important lifestyle changes. Patients
have to take responsibility for a large part of their care and
make real-time decisions about their treatment schedules and
about the doses of insulin they administer several times a day.
The complexity and intensity of self-care in diabetes has been
reported to interfere with the patient’s health-related quality of
life (HRQoL; Wolpert and Anderson, 2001; Escudero-Carretero
et al., 2007).
HRQoL has been widely studied in people with type 1 diabetes,
generally in relation to other aspects such as the presence of
chronic complications (DCCT Research Group, 1996; Hahl et al.,
2002; Jacobson et al., 2013), glycemic control (Hoey et al., 2001;
Tan et al., 2005; Cooke et al., 2015; Stahl-Pehe et al., 2017), disease
duration (Sparring et al., 2013) and the impact of structured
education programs (Speight et al., 2010; Byrne et al., 2012). The
question of how to assess the burden of treatment and its effect on
HRQoL in patients with type 1 diabetes has received less attention
to date.
Determining the impact of disease on patients’ lives is vitally
important in clinical practice because it helps clinicians to detect
needs, identify barriers to self-care and make clinical decisions,
and improve communication with patients (Testa and Simonson,
1996; Huang et al., 2008). Disease-specific instruments for
measuring HRQoL have been shown to be more useful than
general ones, because they are more sensitive to the changes in
the particular disease and provide more detailed information
(Testa and Simonson, 1996). To our knowledge, two specific
instruments for measuring HRQoL in diabetes have been adapted
and validated in Spain: the Audit of Diabetes-Dependent Quality
of Life (ADDQoL) and the Diabetes Quality of Life Measure
(DQoL).
The DQoL (Jacobson et al., 1988) was the first research
instrument to measure HRQoL in diabetes. The DQoL was
designed as part of the DCCT study to assess the impact
of intensive treatment and complications. A Spanish version,
named the EsDQoL, was adapted and validated in the early 2000s
(Millán et al., 2002). The EsDQoL has 43 items grouped into four
dimensions: satisfaction, impact, social/vocational worry, and
diabetes-related worry. Adequate content validity and internal
consistency have been reported in studies of patients with type
2 diabetes (Correr et al., 2008; Pakpour et al., 2012) and with type
1 diabetes (Millán et al., 2002).
However, some of its items have low reliability coefficients
and many of the items on the social/vocational worry subscale
are not applicable to all people (Gibbons and Fitzpatrick, 2009).
The DQoL is a long questionnaire and some questions seem
conceptually difficult, for example: “How often do you find
yourself explaining what it means to have diabetes?” or “... that
your body looks different because you have diabetes?.” Others
seem inappropriate: “... How often do you feel that you have to
go the bathroom more than others?.” And some of the items use
obsolete terms or sound outdated: for example, “insulin reaction,”
or “typewriter” (Gibbons and Fitzpatrick, 2009).
As regards its discriminant validity, the DQoL has
demonstrated sensitivity for identifying patients with chronic
complications (DCCT Research Group, 1996), but not for
intensifying insulin treatment (DCCT Research Group, 1996)
or when applied to patients receiving continuous subcutaneous
insulin infusion (Tsui et al., 2001).
The ADDQol (Bradley et al., 1999) is another widely used
instrument. A version in Argentinian Spanish has been adapted
and validated (Perrotta and Irazola, 2002) and has been used in
several studies of Spanish patients with type 2 diabetes (Botija
Yagüe et al., 2007; Alcubierre et al., 2014; DePablos-Velasco et al.,
2014). The Spanish version has 19 items that refer to the following
areas: leisure activities, work life, travel, vacations, physical
health, family life, friends/social life, sex life, physical appearance,
self-confidence, motivation, society/other people’s reactions, the
future, finances, living arrangements, dependence on others, and
freedom to eat and drink. Previous analyses of the ADDQoL
support a one-dimensional structure for the questionnaire and
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an adequate internal consistency, with Cronbach’s alphas ranging
from 0.81 to 0.95. (Bradley et al., 1999; da Costa et al., 2006; Kong
et al., 2011; Fung et al., 2016). However, in some of its linguistic
adaptations a strict, single-factor structure was not generated
(Ostini et al., 2012; Hirose et al., 2016).
The ADDQol has a complex structure, since it measures
separately the importance that patients attach to each area and
the impact that it has on their lives (Speight et al., 2009). In
addition, its items formulate hypothetical situations that the
patient may or may not be able to imagine (i.e., what life would
be like without diabetes; Gibbons and Fitzpatrick, 2009; Speight
et al., 2009). This is a complex cognitive task, especially for
patients who were diagnosed as children and who have lived with
the disease ever since (type 1 diabetes is usually diagnosed before
the age of 14; Atkinson et al., 2014). Indeed, the Food and Drug
Administration argues against the use of instruments which elicit
hypothetical responses and which require patients to imagine a
desired condition rather than their actual one (The Food and
Drug Administration, 2006).
The ADDQol has shown validity for discriminating between
patients with type 2 diabetes receiving insulin or oral drugs and
between those with better or worse glycemic control (Sundaram
et al., 2007) and has shown sensitivity to change following a
therapeutic education program (DAFNE Study Group, 2002).
However, it did not prove sensitive to change in patients with type
1 diabetes participating in a virtual platform designed to facilitate
self-management (Alvarado-Martel et al., 2015a).
The DQoL and the ADDQoL are used interchangeably in
patients with type 1 and type 2 diabetes. However, therapeutic
guidelines in type 1 diabetes are much more complex and
demanding and require greater commitment from the patient.
Neither, questionnaire makes explicit mention of aspects of self-
care which have a bearing on the HRQoL of patients with type
1 diabetes, such as carbohydrate counting and self-measurement
of glucose, or their concern about hypoglycemia (Wolpert and
Anderson, 2001; Escudero-Carretero et al., 2007; Alvarado-
Martel et al., 2015b).
Finally, these instruments were created some 20 or 30
years ago and the concerns and needs of patients with type
1 diabetes have evolved since then. Today, glucose meters
with calculation tools are available, insulin regimes are more
flexible, access to information is easier thanks to the new
technologies, and there is a growing emphasis on patient-
centered training. All these factors should be taken into account
when measuring HRQoL in people with type 1 diabetes,
since the experience of the disease today is unlikely to be
the same as when the currently available questionnaires were
developed.
In our view there is a need for a new, patient-centered
instrument that is suitable for use in both clinical practice
and research. We developed a new, specific questionnaire
to measure HRQoL in patients with type 1 diabetes: the
ViDa questionnaire for type 1 diabetes (ViDa1). Here,
we describe its structure, reliability, convergent and
discriminant validities, temporal stability, and sensitivity to
change in a heterogeneous sample of patients with type 1
diabetes.
MATERIALS AND METHODS
Creation of the Questionnaire
The development and validation of the instrument consisted of
four stages: 1: Identification of topics relevant to patients, and
generation of the items, 2: Qualitative analysis of items, expert
review, and refinement of the questionnaire, 3: Pilot study, and 4:
Psychometric study of the final questionnaire.
Stage 1: Identification of Topics Relevant to Patients,
and Generation of the Items
The contents of the instrument were based on the information
obtained in a previous qualitative study involving open
interviews with 67 people with type 1 diabetes (Alvarado-Martel
et al., 2015b). These interviews were designed to allow patients to
describe what HRQoL meant to them, and to record their needs
and concerns regarding their disease.
The information obtained from these interviews was
examined and the answers were grouped together to create the
following 19 themes: 1: self-perception of general HRQoL, 2:
social and family relationships, 3: leisure and leisure time, 4:
limitations on work, 5: sex life, 6: physical activity, 7: chronic
complications, 8: physical/psychological well-being, 9: sleep,
10: satisfaction with treatment, 11: glucose measurement, 12:
involvement in and satisfaction with glycemic control, 13:
acceptance of disease, 14: motivation, 15: flexibility in diet, 16:
satisfaction with the level of knowledge of diabetes, 17: daily
stress caused by self-care, 18: fear of/worry about hypoglycemia,
and 19: worry about hyperglycemia.
A qualitative analysis of the themes showed that many of
them were interrelated and could be grouped a priori into a
series of broader categories: General quality of life, or Well-
being (self-perception of general HRQoL, physical activity,
physical/psychological well-being, sleep), Self-care of diabetes
(satisfaction with treatment, glucose measurement, involvement
and satisfaction with glycemic control, motivation, flexibility
in diet, satisfaction with one’s knowledge of the disease),
Interference of diabetes in the person’s daily life and limitations
(social and family relations, leisure and free time, limitations on
work, sex life, chronic complications, acceptance of illness, daily
stress caused by self-care) and Worry about chronic and acute
complications of the disease (fear of/worry about hypoglycemia,
worry about hyperglycemia and chronic complications). This
theme grouping into four defined categories constituted our
initial theoretical hypothesis.
Based on these 19 themes, a list of 53 disease-related issues was
identified (e.g., flexibility in my diet, acceptance of my diabetes)
that reflected patients’ attitudes and behaviors (Table 1). All
issues were evaluated by 10 different patients who indicated on
a Likert scale (1 = “none at all” to 10 = “a great deal”) the
importance that they attached to them in their daily lives. A
descriptive analysis indicated that all were considered important.
Subsequently, 54 items were created that covered all the
information that the patients had identified as relevant and
contained in the 53 issues. This process gave rise to the initial
version of the questionnaire, which used Likert type responses (1
= “strongly disagree” to 5= “strongly agree”).
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TABLE 1 | Issues on the Health-Related Quality of Life Questionnaire.
1 Responsibility for my diabetes
2 Motivation for self-care of my diabetes
3 Involvement in the care of my diabetes
4 Autonomy in the management of my diabetes
5 The staff who take care of me should have knowledge of diabetes
6 The time spent on the care of diabetes
7 Level of knowledge of/training in diabetes
8 The adjustment of insulin to the diet
9 Pharmacological treatment
10 Flexibility in the diet
11 Everyday stress due to care duties
12 The feeling of being different
13 Limitations on food
14 Eating out
15 Physical activity/exercise
16 Limitations on work and professional activity due to diabetes
17 Being seen differently or treated differently because of my diabetes
18 Satisfied with glycemic control
19 Leisure time for doing things that I like
20 The fact that others know I have diabetes
21 Injecting insulin
22 Constantly thinking about how I am feeling, about my level of glycemia
23 Carrying out the glucose measurements
24 Fear about having hypoglycemias
25 The possible complications of the illness
26 The distress caused by this illness
27 My sex life
28 My sleep, the time I rest and sleep
29 Feeling good physically
30 My physical appearance
31 Feeling good psychologically
32 Being limited by diabetes and/or its complications
33 Having a good relationship with the health staff who take care of my
diabetes
34 Worry about third parties such as partner/children
35 My relationship with my family
36 My relationship with friends/acquaintances/colleagues at work
37 The fact that the people around me are familiar with diabetes
38 Feeling judged by the people around me
39 Being in good health
40 Feeling limited due to my health
41 Being able to carry out my everyday activities
42 Being able to have a social life, like going out to supper with friends,
having a drink, going dancing, etc.
43 Experiencing physical pain
44 Not feeling limited by having diabetes
45 Counting carbohydrates for a more flexible diet
46 Worry about going into hospital
47 Feeling overwhelmed by diabetes
48 Pressure from others about whether I’m doing it well or not
49 Worry about hypoglycemias
50 Having illnesses other than diabetes
51 The possibility of developing complications in the future
52 Worry about having high glucose levels
53 Being able to choose the profession I want without being hampered by
my diabetes
Stage 2: Qualitative Analysis of the Items, Expert
Review, and Refinement of the Questionnaire
Once the initial version of the questionnaire was obtained, a
qualitative analysis of the items was carried out to determine
whether there were any problems of comprehension or any
possible ambiguity in their interpretation. To this end, 10 more
patients were selected to answer the questionnaire. While they
were doing so, they were asked whether they understood the
items, whether the items represented their concerns and needs,
and so on.
In turn, this initial 54-item version of the questionnaire was
evaluated by a group of endocrinologists, nurse educators and
psychologists, who identified the items that were potentially
ambiguous and might cause confusion, and also the issues that
were overrepresented. Each of the items was evaluated and
consensus was reached and as a result 14 were eliminated. Thus,
this led to a questionnaire comprised of 40 items.
Stage 3: Pilot Study
To analyze the structure underlying the questionnaire and to
obtain information on its psychometric properties, a pilot study
of this 40-item version was carried out with 150 patients with
type 1 diabetes attending routine visits at the Endocrinology
andNutrition Service of the Complejo Hospitalario Universitario
Insular Materno-Infantil in Gran Canaria. As a result of the
analyses (see the “Results” Section) the final questionnaire was
reduced to 34 items.
Stage 4: Psychometric Study of the Final
Questionnaire
In this last stage, the psychometric properties of the 34-item
questionnaire (hereafter ViDa1) were explored in a sample of 578
patients with type 1 diabetes. In order to contrast the factormodel
initially obtained in the PCA, a CFA (N = 428) was performed
using the Unweighted Least Squares Method.
Procedure
A multicenter study was carried out at seven hospitals in
Spain. The investigation was led by the Complejo Hospitalario
Universitario Materno-Infantil of Gran Canaria, which recruited
the highest number of patients. The study was approved by the
Ethics Committees of the corresponding hospitals.
Patients were enrolled at the Endocrinology and Nutrition
Services during routine medical visits between February 2014
and May 2016. Participants were informed of the purpose of the
study and were invited to participate, then given an informed
consent document to complete and sign and issued with a dossier
containing the questionnaires detailed in the “Instruments”
section.
The patients completed the dossier in the waiting room,
where they were able to ask questions or receive help from the
researcher. The dossier took∼30min to complete.
Participants
Five hundred and ninety-three people with type 1 diabetes were
recruited. Fifteen who did not complete all the items of the
questionnaire ViDa1 were excluded, and so the final sample
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consisted of 578 patients, of whom 150 participated in the pilot
study.
The following exclusion criteria were applied: age under 14
years (minors are treated at Pediatric Units, and in addition their
responses may not reflect their “real” quality of life because the
responsibility for the disease is usually shared with their parents);
pregnant women, due to the increased self-care characteristic of
pregnancy; and all those who could not complete the dossier due
to language problems.
The majority of the sample (70.2%) were from the Hospital
Universitario Insular Materno Infantil of Gran Canaria, 10.4%
from the Hospital Universitario de Gran Canaria Doctor Negrín,
11.4% from the Germans Trias i Pujol University Hospital
(Badalona, Barcelona) 3.8% from the Ramón y Cajal University
Hospital (Madrid) 2.2% from the University Hospital La Paz
(Madrid) 0.5% from Parc Taulí Hospital (Sabadell, Barcelona)
and 1.4% from the D-Médical private clinic (Madrid). The
age range was 14–71 years and the mean disease duration
was 18 years. Table 2 describes the characteristics of the study
participants.
Instruments
Structured Self-administered Data Collection Sheet
This data sheet was designed specifically for the study and it
covered the following sociodemographic and clinical variables:
sex, age [participants were categorized as adolescents (14–20
years), young (21–30 years), adults (31–50 years), and older
(51–71 years)], hospital center, level of education (illiterate,
primary, secondary, and university studies), employment
situation, living arrangements, duration of disease, type of
drug treatment, glycemic control (using the most recent
concentration in the last 30 days of glycosylated hemoglobin
(HbA1c) standardized against NGSP/DCCT), treatment with
psychoactive drugs, cardiovascular risk factors (diagnosis of
hypertension, dyslipidemia, smoking, and obesity), carbohydrate
count, presence, and type of chronic complications and
the limitation they represented on participants’ daily lives,
number of hypoglycemic episodes per week, and presence of
acute complications (admissions for severe hyperglycemia or
hypoglycemia). Medical variables were confirmed with the
patients’ medical history.
In addition to the ViDa1 questionnaire, the following
instruments were administered:
Diabetes Quality of Life (Jacobson et al., 1988) in its
adapted and validated version in Spanish (Millán et al.,
2002). The instrument is composed of 43 items distributed
in four dimensions: satisfaction (15 items), impact (17 items),
social/vocational worry (7 items), and diabetes-related worry (4
items). A Likert scale format is used for the responses (1 = “very
satisfied” to 5 = “not satisfied” for the satisfaction subscale, and
1 = “never” to 5 = “always” for the others). A total score and
scores for each of the different subscales are obtained. Lower
scores on the full scale indicate better HRQoL. In our sample
Cronbach’s alphas were 0.92 for the full questionnaire,0.86 for
satisfaction,0.88 for impact,0.78 for social/vocational worry and
0.73 for diabetes-related worry.
TABLE 2 | Participants’ characteristics. (N = 578).
Sex (% women) 41.7
Age (years)* 35.2 (11.9)
Duration of illness (years)* 18.0 (10)
HbA1c (%)
* 7.9 (1.3)
Insulin treatment (%)
Multiple doses 77.5
Continuous perfusion pump 17.8
Carbohydrate count (%) 64.2
At least one event (% patients)
Mild hypoglycemias (per week) 87.7
Severe hypoglycemia (since diagnosis) 33.0
Admission due to hyperglycemia (since diagnosis) 26.6
Psychopharmacological treatment (%) 14.7
Associated cardiovascular risk factors (%) 41.2
Chronic complications (%) 29.6
Retinopathy 23.2
Nephropathy 9.9
Neuropathy 11.1
Macroangiopathy 2.9
Limitation due to complications (%) 8.8
Living arrangements (%)
With family 72.3
With a partner 18.4
Alone 7.5
Other 1.9
Education (%)
Illiterate 2.1
Primary education 29.8
Secondary education 39.3
University studies 28.9
Employment status (%)
Student 17.0
In employment 52.1
Unemployed 23.5
Other 7.4
*The data are expressed as mean (standard deviation).
The Satisfaction With Life Scale (SWLS; Diener et al., 1985).
The validated Spanish version was used (Vázquez et al., 2013).
Responses are recorded on a Likert scale (0= “strongly disagree”
to 6= “strongly agree”) and the score range is 0–30. Higher scores
indicate higher life satisfaction. The Cronbach’s alpha for the total
scale in our sample was 0.84.
The Positive and Negative Affect Schedule (PANAS; Watson
et al., 1988). The validated short form of the schedule was used
(Thompson, 2007). This is a self-report measure of 10 items that
evaluate negative and positive affect (5 items each). Responses
are recorded on a Likert scale (0 = “not at all” to 6 = “totally”)
with a score range of 0–30 for each subscale. Higher scores on
each subscale indicate a greater increase in positive or negative
emotions. Cronbach’s alphas in our sample were 0.78 for negative
affect and 0.85 for positive affect.
The General Self-Efficacy Scale (GSE; Jerusalem and
Schwarzer, 1992). The validated Spanish version was
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administered (Baessler and Schwarcer, 1996). This scale
measures respondents’ expectations about their ability to cope
adequately with a problematic situation. Responses are recorded
on a Likert scale (1 = “not at all” to 5 = “totally”) and the
score range is 1–50. High scores indicate a higher perception of
self-efficacy. In our study Cronbach’s alpha for the GSE was 0.89.
The Hospital Anxiety and Depression Scale (HADS; Zigmond
and Snaith, 1983). The validated Spanish version was applied
(Tejero et al., 1986). This is a self-report measure of 14 items
that evaluate symptoms of anxiety and depression (seven items
each). Responses are recorded on a Likert scale (0–3) and the
score range is 0–21 for each subscale. In our study Cronbach’s
alpha for anxiety and depression were 0.55 and 0.79, respectively.
Problem Areas in Diabetes Scale (PAID; Welch et al., 1997).
The validated Spanish-language version was used (Welch et al.,
2007). The scale has 20 items which are answered on a Likert
scale (0 = “not a problem” at 4 = “a very serious problem”).
The scores obtained range from 0 to 100. Higher scores indicate
greater emotional distress related to diabetes. In our study the
Cronbach’s alpha was 0.94.
Statistical Analysis
Data were analyzed using the statistical software SPSS version
23.0, Armonk, New York, IBM Corp. The sampling adequacy
was calculated using the Kaiser-Meyer-Olkin (KMO) index and
the Bartlett sphericity test, which showed that factor analysis was
appropriate for this dataset.
To examine the underlying structure or dimensions of the
ViDa1 questionnaire, a Principal Component Analysis (PCA)
with orthogonal varimax rotation was performed, since the
initial theoretical hypothesis suggested that the factors were
independent of each other and that there was no common factor.
The relevant information mentioned by the patients was grouped
into four different dimensions.
In order to extract the correct number of factors, Kaiser’s
criterion was used, based on the retention of factors with
eigenvalues above 1 (Kaiser, 1958), along with the scree test based
on the graphical representation of all eigenvalues (Cattell, 1966)
and the initial theoretical hypothesis (Fabrigar et al., 1999).
Items in the pilot study that did not load on any factor, had
factor loads lower than 0.40, were overrepresented, or whose
elimination improved the Cronbach alpha were eliminated.
Descriptive statistics were calculated for all items (mean,
standard deviation, item-total correlation, and item-total
correlation if the item was deleted). Reliability was evaluated by
calculating the Cronbach’s alpha coefficient.
To confirm the four-factor model a Confirmatory Factor
Analysis (CFA) was performed in a second sample. CFA is the
method most commonly used to obtain evidence of construct
validity since it reports the internal structure of the instrument
(Zumbo, 2007). CFA was performed with the LISREL version
8.54 program through the Unweighted Least Squares Method;
this estimation method was used because it has no limitations
with respect to sample size and does not require multivariate
normality. It is based on the polychoric correlation matrix and
is more suitable for Likert type scales that apply an ordinal scale
of measurement (Morata-Ramirez et al., 2015).
The following fit indices were considered: Chi-square/degrees
of freedom ratio (χ2/df: a value <3 was taken to indicate a
good fit), the root mean square error of approximation (RMSEA;
values close to 0.06 indicate a good fit), the normative fit index
(NFI), the non-normalized fit index (NNFI), the comparative fit
index (CFI), the goodness-of-fit index (GFI), and the adjusted
goodness-of-fit index (AGFI). Values>0.90 suggest a satisfactory
fit, and values of 0.95 or higher an optimal fit (Hu and Bentler,
1999).
The study of convergent and discriminant validity was carried
out with the Pearson’s correlation coefficient following Campbell
and Fiske (1959). Those authors argued that, for measures to be
valid, the measures of the same construct must correlate highly
with each other (convergent validity), and that this correlation
must be greater than that between the measures proposed
for another construct (discriminant validity). The correlation
between HRQoL measured by the various subscales of the ViDa1
questionnaire and the following constructs was studied: HRQoL
in diabetes (EsDQOL subscales), satisfaction with life (SWL),
self-efficacy (GSE), negative and positive affect (PANAS), anxiety
and depression (HADS), and distress due to diabetes (PAID).
ANOVAs and Pearson correlations were performed to provide
discriminant validity for the ViDa1 questionnaire in order to
determine whether the ViDa1 scores could discriminate between
groups that are known to differ in terms of the variable of interest.
For the multiple comparisons following statistically significant
ANOVAs, the Bonferroni correction was applied to control for
the probability of a type I error.
The test-retest reliability (temporal stability) was measured
with the Pearson correlation in 95 participants. The sensitivity
to change was evaluated with Student’s t-test for paired
samples in 46 subjects. Descriptive statistics were calculated for
all quantitative variables (mean and standard deviation) and
percentages for categorical variables. All the studied variables
presented a normal distribution, as shown by the Kolmogorov-
Smirnov test.
RESULTS
Pilot Study of the ViDa1 Questionnaire in
150 Patients
The adequacy of the data for PCA was supported by the KMO
index, with a value of 0.83, and by the Bartlett sphericity test
(χ2 = 2771.162; df = 780; p< 0.001).
The PCA with varimax rotation showed 11 components
with eigenvalues above 1 (Kaiser, 1958). However, the scree
test (Cattell, 1966) showed an inflection point in the fourth
factor. This solution was also supported by the initial theoretical
hypothesis (Fabrigar et al., 1999).
Descriptive analyses were performed for each of the 40
items on the ViDa1. Six items that were overrepresented were
removed, some because they had negative loadings on all factors
and others because their elimination improved the Cronbach’s
alpha. A new PCA with varimax rotation was performed without
the eliminated items and forcing the extraction to four factors.
As a result, a 4-factor matrix was obtained with 34 items
which accounted for 45% of the total variance. All factors were
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well defined, since all the factor-relevant items had loadings
above 0.40.
Psychometric Study of the ViDa1
Questionnaire in 578 Patients
Dimensions of the Questionnaire
The adequacy of the data for PCA was supported by the KMO
index (value of 0.89) and by the Bartlett sphericity test (χ2 =
5222.845; df = 595; p< 0.001).
The PCA with varimax rotation showed seven components
with eigenvalues above 1 (Kaiser, 1958). However, the scree
test (Cattell, 1966) showed an inflection point in the fourth
factor. This solution was also supported by the initial theoretical
hypothesis and by the results obtained in the pilot study. As a
result, it was decided to force the retention to four factors.
As Table 3 shows, the result was a matrix of 34 items
with loadings >0.40 on four factors, which account for 45%
of the total variance. Although two items had loads of above
0.40 on more than one factor, they were included in the
factor in which the loading and theoretical significance were
greater.
The ViDa1 questionnaire has a multidimensional
structure with four main factors: Interference of diabetes in
everyday life (composed by 12 items), Self-care (11 items)
Well-being (six items), and Worry about the disease (five
items).
Reliability
Internal consistency was evaluated with Cronbach’s alpha, which
was 0.86 for the Interference subscale, 0.84 for Self-care, 0.76 for
Well-being and 0.71 for Worry. All subscales had coefficients
>0.70 and were thus considered adequate (Gliem and Gliem,
2003).
Descriptive Analysis
Table 4 shows the corrected item-total subscale correlations,
which ranged from 0.36 to 0.71. All the items are well represented
in the different factors or dimensions of the questionnaire.
The multidimensionality of the ViDa1 makes it possible to
obtain a total score for each subscale (Table 5) by adding together
the scores for each item. For correct interpretation, items 12, 23,
and 27 are reversed.
Table 6 shows the correlations between the subscales (factors)
of the ViDa1.
Confirmatory Factor Analysis (CFA)
In order to contrast the four-factor model initially obtained in
the PCA, a CFA (N = 428, which did not include the 150 in the
pilot study) was performed using the Unweighted Least Squares
Method. To determine the goodness of fit of the proposed model,
the overall fit indices obtained were interpreted. There were
no missing data. The four-factor model developed in the pilot
study, achieved optimal fit: the χ2/df index was 2601.93/554,
statistically significant (p < 0.0001) and below 3, and the NFI
(0.94), NNFI (0.96), IFC (0.96), GFI (0.95), and IFI indices
(0.96) were all above.90 (Hu and Bentler, 1999). The RMSEA
also presented an appropriate value, not higher than 0.06 (CI =
0.056–0.064; Hu and Bentler, 1999). Since the overall fit indices
were adequate, we concluded that the model represents the
behavior of the data reasonably well. In summary, the responses
of the participants supported the method used to develop the
instrument.
Convergent-Discriminant Validity
Convergent-discriminant validity was evaluated through
Pearson’s correlations between the four subscales of ViDa1 and
other related measures.
The four subscales of ViDa1 correlated strongly with the
four subscales of another questionnaire on HRQoL in diabetes
(EsDQoL) and with the satisfaction with life scale (SWLS). The
self-efficacy and positive affect variables also correlated with the
subscales of the ViDa1, although more weakly. Anxiety and
depression and distress due to diabetes were inversely correlated
with the ViDa1 subscales. Correlations between measures are
presented in Table 7.
Known-Groups Validity
To provide more data on the validity of ViDa1, we explored
whether there were differences in the ViDa1 questionnaire scores
in certain groups which are known to differ from one another and
which are relevant in clinical practice.
As can be seen in Table 8, significant differences were found
in the scores of the four subscales of the ViDa1 questionnaire
with respect to gender, educational level, age, carbohydrate count
in the diet, type of treatment, presence of an additional illness,
treatment with psychoactive drugs, and the presence of chronic
complications.
Bonferroni’s post-hoc multiple comparisons revealed
differences with respect to age in Well-being and Worry.
The 14–20 year age group had higher Well-being scores than the
31–50 (t = 2.8, p < 0.001) and 51–71 year age groups (t = 2.4,
p= 0.042) and lower scores onWorry than the 31–50 year group
(t = 1.8, p = 0.029). Lower scores on Worry were also found in
participants who had completed secondary school (t = 1.4, p =
0.022) and university (t = 2.0; p < 0.001) than in those who had
completed only primary education.
As for type of pharmacological treatment, people on multiple
insulin dose treatment presented higher Interference scores than
those receiving continuous infusion pump treatment (t = 2.9;
p= 0.021) and lower Self-care scores (t = 3.7; p< 0.001).
Next, the relationships between the scores on the subscales of
ViDa1 with HbA1c and disease duration were studied. HbA1c
correlated with scores on Worry (r = 0.10, p = 0.028) and
inversely with Self-care (r = −0.39, p < 0.001) and Well-being
(r = −15, p < 0.001). Patients with HbA1c of 7% or below had
higher scores on Self-care [(45.2 ± 7.2 vs. 40.5 ± 7.8); t = 5.2; p
< 0.001] and lower scores on Worry [(18.1 ± 4.3 vs. 19.2 ± 4.1);
t= 2.3; p< 0.021]. Disease duration correlated inversely with the
Well-being subscale (r =−17, p< 0.001).
Temporal Stability
Ninety-five patients repeated the ViDa1 questionnaire between
15 and 25 days after their initial participation. The correlations
obtained between the initial test and re-test were high for all
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TABLE 3 | Principal Component Analysis with varimax rotation (N = 578).
Items Components
1 2 3 4
1 Having diabetes is a problem for my social relationships (i.e., with friends, work colleagues, partner, etc.) 0.70 −0.03 0.18 0.05
2 I feel different because of my diabetes. 0.68 0.12 0.10 0.15
3 Having to inject insulin is a daily problem for me. 0.66 0.27 −0.13 0.14
4 Having diabetes limits my social life and free time activities (eating out, celebrations, trips, etc.). 0.65 0.16 −0.07 0.26
5 My life has been changed by having diabetes. 0.59 0.11 0.03 0.26
6 Having diabetes makes my relationship with my family more difficult. 0.59 0.03 0.24 0.00
7 I feel limited professionally by my diabetes. 0.58 0.00 0.12 0.24
8 In spite of my diabetes I can lead a normal life. 0.56 0.36 0.20 0.07
9 One or more complications of my diabetes worsen my quality of life because it limits/they limit me physically. 0.51 0.01 0.41 0.16
10 Everyday life with diabetes represents an added source of stress. 0.49 0.15 0.26 0.38
11 I worry that other people know that I have diabetes. 0.48 0.14 0.04 0.04
12 My sex life is limited by my diabetes. 0.41 0.01 0.23 −0.05
13 I am happy with my involvement in the everyday self-care of my diabetes. 0.00 0.71 0.34 0.08
14 The level of training/knowledge I have about my diabetes helps me to maintain good control over it. 0.04 0.69 0.05 0.05
15 The training I have in carbohydrate counting allows flexibility in my diet. 0.11 .65 −0.09 0.08
16 I am happy with the way I cope with my diabetes. 0.06 0.63 0.46 0.10
17 I am motivated to take part in the care of my diabetes. 0.04 0.60 0.28 −0.01
18 I adjust the insulin dose to my diet to obtain good control. 0.04 0.60 0.00 −0.08
19 I am satisfied with my pharmacological treatment because it helps me to control my diabetes. 0.12 0.59 0.07 −0.10
20 I am satisfied with my glycemic control at the moment (glycosylated hemoglobin). −0.10 0.57 0.34 0.10
21 The management of my diabetes is a part of my normal everyday life. 0.30 0.52 0.25 0.04
22 I consider that I have flexibility and freedom in my diet in spite of my diabetes. 0.25 0.44 0.00 0.13
23 I find it hard to carry out the daily controls (glycemias). 0.20 0.40 0.12 −0.00
24 I get plenty of rest and I sleep well at night. 0.14 0.14 0.66 0.15
25 I feel fine physically. 0.19 0.28 0.66 0.04
26 I feel fine psychologically. 0.30 0.26 0.55 0.18
27 I have other illnesses as a result of my diabetes which have a negative effect on my quality of life. 0.32 −0.08 0.50 0.00
28 I am satisfied with the time I spend doing physical activity. −0.05 0.27 0.47 0.03
29 I think that in general my quality of life is good. 0.31 0.36 0.49 0.14
30 I am frightened of having hypoglycemias (fall in sugar level). 0.16 −0.04 0.07 0.68
31 I often worry about having a hypoglycemia. 0.20 −0.07 0.05 0.68
32 I feel worried when I have high glycemia. 0.04 −0.03 0.00 0.63
33 I often worry about having complications in the future due to my diabetes. 0.12 0.09 0.10 0.67
34 I often worry about being admitted to hospital because I can’t control my diabetes. 0.19 0.26 0.16 0.53
Factors Eigen value % Variance Accumulated % of Variance
1 8.4 24.9 24.9
2 3.4 10.0 35.0
3 1.7 5.2 44.2
4 1.6 4.7 44.9
In bold, the factor weights ≥ 0.40.
subscales: Interference (r =0.78, p < 0.001), Self-care (r = 0.78,
p < 0.001), Well-being (r = 0.77, p < 0.001), and Worry (r =
0.60, p< 0.001).
Sensitivity to Change
To establish whether the ViDa1 questionnaire was sensitive
to detecting changes after a new treatment or after an
educational program, 46 patients from the study who
completed the questionnaire were assessed 7–15 days before
starting the new treatment or program, and then between
30 and 45 days later. Fifteen of these patients received
an out-patient, 5-day, structured group therapy education
program (the ANAIS program) which promotes a flexible
diet with insulin intensification. Another 23 patients started
subcutaneous insulin infusion pump treatment and eight,
treatment with insulin degludec, a long-acting basal insulin.
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TABLE 4 | Descriptive analysis of the ViDa1 questionnaire. (N = 578).
M SD Corrected ítem-total Cronbach’s alpha
correlation if the item
is eliminated
INTERFERENCE IN LIFE
Having diabetes is a problem for my social relationships (i.e., friends, work colleagues, partner, etc.) 1.7 1.1 0.59 0.85
I feel different because of my diabetes. 2.3 1.3 0.65 0.85
Having to inject insulin is a daily problem for me. 2.5 1.3 0.56 0.85
Having diabetes limits my social life and free time activities (eating out, celebrations, trips, etc.). 2.7 1.4 0.62 0.85
My life has been changed by having diabetes. 3.6 1.3 0.58 0.85
Having diabetes makes my relationship with my family more difficult. 1.7 1.1 0.52 0.85
I feel limited professionally by my diabetes. 2.7 1.4 0.56 0.85
One or more complications of my diabetes worsen my quality of life because it limits/they limit me physically. 2.4 1.3 0.54 0.85
Everyday life with diabetes represents an added source of stress. 3.0 1.3 0.54 0.85
I worry that other people know that I have diabetes. 2.0 1.3 0.58 0.85
My sex life is limited by my diabetes. 2.1 1.2 0.43 0.86
In spite of my diabetes I can lead a normal life. 2.0 1.1 0.38 0.86
SELF-CARE
I am happy with my involvement in the everyday self-care of my diabetes. 3.6 1.1 0.71 0.80
The level of training/knowledge I have about my diabetes helps me to maintain a good control. 4.1 0.9 0.57 0.82
The training I have in carbohydrate counting allows flexibility in my diet. 3.8 1.1 0.47 0.82
I am happy with the way I cope with my diabetes. 3.5 1.1 0.68 0.81
I am motivated to take part in the care of my diabetes. 4.0 1.0 0.57 0.82
I adjust the insulin dose to my diet to obtain good control. 4.4 0.9 0.46 0.82
I am satisfied with my pharmacological treatment because it helps me to control my diabetes. 4.1 1.0 0.49 0.82
I am satisfied with my glycemic control at the moment (glycosylated hemoglobin). 3.0 1.3 0.55 0.82
The management of my diabetes is a part of my normal everyday life 4.1 1.0 0.52 0.82
I consider that I have flexibility and freedom in my diet in spite of my diabetes. 3.6 1.2 0.34 0.84
I find it hard to carry out the daily controls (glycemias). 3.3 1.4 0.36 0.84
WELL-BEING
I get plenty of rest and I sleep well at night. 3.7 1.3 0.55 0.70
I feel fine physically. 3.7 1.2 0.67 0.67
I feel fine psychologically. 3.8 1.2 0.58 0.69
I have other illnesses as a result of my diabetes which have a negative effect on my quality of life. 4.0 1.2 0.30 0.77
I am satisfied with the time I spend doing physical activity. 3.0 1.4 0.54 0.71
I think that in general my quality of life is good. 4.0 0.9 0.37 0.75
WORRY ABOUT THE DISEASE
I am frightened of having hypoglycemias (fall in sugar level). 3.4 1.3 0.51 0.64
I often worry about having a hypoglycemia. 3.7 1.2 0.52 0.64
I feel worried when I have high glycemia. 4.3 0.9 0.52 0.64
I often worry about having complications in the future due to my diabetes. 4.1 1.0 0.36 0.70
I often worry about being admitted to hospital because I can’t control my diabetes. 3.2 1.4 0.44 0.68
M, mean; SD, standard deviation. The items are scored on a Likert scale (1 = strongly disagree, 2 = agree, 3 = neither agree or disagree, 4 = agree, 5 = strongly agree).
The ViDa1 subscales Interference [(31.1 ± 9.3 vs. 29.5 ±
9.1); t = 9.9; p < 0.054] and Self-care [(40.8 ± 6.4 vs.
44.5 ± 6.6); t = 4.3; p < 0.001)] proved to be sensitive to
change.
DISCUSSION
Type 1 diabetes is a chronic disease with complex
therapeutic demands. This high burden of treatment
may have a strong impact on patients’ lives and their
HRQoL.
Two specific instruments are currently available for measuring
HRQoL in people with type 1 diabetes, the DQoL and the
ADDQoL. However, neither of these questionnaires includes
important aspects of patient care such as carbohydrate count
in the diet, self-measurement of glucose, and worry about
hypoglycemia; they were both developed some 20 or 30 years ago
and the treatment of diabetes has evolved since then. In addition,
they are designed to measure HRQoL in both type 2 and type 1
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TABLE 5 | Descriptive analysis of the ViDa1 according to subscale. (N = 578).
M SD Mín. Max. N items Scale
Interference 29.1 10 12 57 12 (12–60)
Self-care 41.6 7.9 15 55 11 (11–55)
Well-being 22.5 5.1 8 30 6 (6–30)
Worry 19.0 4.1 5 25 5 (5–25)
M, mean; SD, standard deviation; Min, minimum; Max, maximum.
TABLE 6 | Correlations between the ViDa1 subscales (N = 578).
Self-care Well-being Worry
Interference −0.39** −0.53** 0.46**
Self-care 0.53** −0.20**
Well-being −0.31**
**p < 0.001.
TABLE 7 | Correlations between the ViDa1 subscales and other scales (N = 578).
Interference Self-care Well-being Worry
Satisfaction (EsDQoL) 0.62** −0.64** −0.68** 0.33**
Impact (EsDQoL) −0.84** 0.72** 0.58** −0.56**
Worry: Social/vocational (EsDQoL) 0.45** −0.32** −0.40** 0.34**
Worry: diabetes-related (EsDQoL) 0.46** −0.35** −0.43** 0.56**
Satisfaction with life (SWL) −0.52** 0.41** 0.55** −0.32**
Positive affect (PANAS-P) −0.41** 0.31** 0.48** −0.20**
Self-efficacy (EAG) −0.30** 0.31** 0.36** −0.20**
Negative affect (PANAS-N) 0.42** −0.32** −0.45** 0.36**
Anxiety (HADS-A) 0.45** −0.38** −0.53** 0.39**
Depression (HADS-D) 0.49** −0.41** −0.61** 0.32**
Distress due to diabetes (PAID) 0.44** −0.38** −0.34** 0.45**
**p < 0.001. In bold, the highest correlations of each subscale on the ViDa1 with the
subscales of the EsDQoL. The scores on the EsDQoL are not inverted, and for this reason
the correlations are negative.
diabetes, despite the fact that the two diseases require different
therapeutic approaches.
The objective of this study was to develop a new questionnaire
for measuring HRQoL in people with type 1 diabetes and
to provide information on its psychometric properties. The
instrument, the ViDa1, was designed to reflect patients’
perceptions of what it means to live with type 1 diabetes, so
as to be able to assess the impact of the disease on their
lives.
With respect to the questionnaire’s psychometric properties,
PCA revealed a multidimensional structure with four main
dimensions: Interference of diabetes in everyday life,
Self-care, Well-being, and Worry about the disease. The
questionnaire presented adequate reliability, as evaluated with
Cronbach’s alpha. All subscales had alpha-values >0.70, as
required by current recommendations (Gliem and Gliem,
2003).
TABLE 8 | Differences between groups using ANOVA. (N = 578).
N Int. Self. Well. Worry.
Total 578 29.1 (10) 41.6 (7.9) 22.5 (5.1) 19.0 (4.1)
SEX
Male 241 28.5 (9.9) 41.9 (8.0) 23.8 (4.8) 18.3 (4.2)
Female 337 29.6 (10) 41.4 (7.8) 21.6 (5) 19.4 (4.1)
F-value 1.7 0.4 27.2*** 6.5**
AGE (YEARS)
14–20 77 26.9 (10.6) 41.5 (7.8) 24.7 (4.5) 17.5 (4.9)
21–30 126 27.8 (8.9) 40.2 (7.7) 23.1 (4.7) 18.5 (3.7)
31–50 322 30.0 (10) 41.8 (8.1) 21.8 (5.2) 19.3 (4)
51–71 53 30.3 (10.6) 43.5 (7.1) 22.3 (4.5) 19.4 (4.4)
F-value 3.0** 1.8 7.5*** 3.1**
EDUCATION
Illiterate 12 34.4 (11.7) 37.0 (9.3) 21 (6.9) 20 (3)
Primary studies 172 29.7 (10.5) 40.7 (8.1) 22.2 (5.1) 20.1 (4)
Secondary studies 227 28.9 (9.8) 41.9 (7.9) 22.4 (5.2) 18.7 (4.3)
University studies 167 28.4 (9.5) 42.2 (7.7) 23.2 (4.6) 18.0 (3.9)
F-value 1.6 1.4 1.7 5.8**
TREATMENT
MDI 448 29.5 (9.7) 41 (7.9) 22.6 (5.1) 18.8 (4.2)
Pump 103 26.5 (10) 44.7 (6.6) 22.4 (4.7) 19.5 (3.8)
Oral injections 27 32.9 (11.9) 38.4 (9.3) 21.2 (6.1) 19.8 (3.7)
F-value 5.7** 8.5*** 1 1.1
CARBOHYDRATE COUNT
Yes 370 28.8 (10.1) 43.2 (7.2) 22.9 (4.7) 18.7 (4.2)
No 207 29.7 (9.6) 38.1 (8.3) 21.9 (5.5) 19.5 (4.1)
F-value 1.1 42.6*** 4.4** 3.1
ADDITIONAL ILLNESS
Yes 225 31.2 (10) 40.9 (8.1) 20.9 (5.4) 19.7 (4.3)
No 353 29.1 (9.7) 41.9 (7.8) 23.6 (4.5) 18.6 (4)
F-value 16*** 1.4 41.7*** 6.9*
CHRONIC COMPLICATIONS
Yes 171 30.3 (9.8) 41 (8) 20.4 (5.3) 19.5 (3.8)
No 407 28.6 (10) 41.9 (7.9) 23.4 (4.7) 18.7 (4.3)
F-value 3.3 1.1 47.5*** 2.9
PSYCHOACTIVE DRUGS
Yes 85 28.4 (9.1) 39.5 (8.8) 17.8 (4.7) 18.6 (3.7)
No 493 33.0 (10.0) 42.0 (7.6) 23.3 (4.6) 20.5 (4.2)
F-value 15.2*** 6.1* 102.6*** 12.2**
Int, Interference; Self, Self-care; Well, Well-being; MDI, multiple daily injections of insulin
The table shows means, standard deviations in brackets and the F-value with its
significance *p < 0.05. **p < 0.01. ***p < 0.001. Significant F-values are highlighted in
bold values.
The CFA also revealed a good fit of the initially proposed
model with the PCA, as indicated by the fit indices (Hu and
Bentler, 1999).
As for the questionnaire’s convergent-discriminant validity,
the associations it presented were as expected. Its subscales
correlated highly with the four subscales of the EsDQoL, since
both instruments measure the same construct, and also with the
satisfaction with life scale (SWLS), another construct previously
associated with quality of life (Diener et al., 1985). ViDa1
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also correlated inversely with constructs that have been linked
with HRQoL such as anxiety and depression (Hassan et al.,
2006; Schram et al., 2009) and emotional distress in diabetes
(Strandberg et al., 2014).
The ViDa1 questionnaire discriminated between variables that
are relevant in the treatment of patients with type 1 diabetes:
glycemic control, carbohydrate count, type of insulin treatment,
and presence of chronic complications.
A higher HbA1c value was associated with lower scores
on Well-being and Self-Care and with higher scores on
Interference and Worry. An HbA1c of 7% or less was
associated with higher scores on Self-Care and lower scores
on Worry. It seems fair to assume that people who involve
themselves more in self-care tasks will have lower levels
of HbA1c; as this indicator has been associated with the
development of chronic complications, having a lower HbA1c
may be associated with a lower level of worry about this
possibility. A better HRQoL has previously been associated with
better glycemic control (Hoey et al., 2001; Stahl-Pehe et al.,
2017).
Patients who performed carbohydrate counts had higher Self-
care and Well-being scores (see Table 8). Indeed, a flexible
diet with carbohydrate counts has previously been linked to
higher HRQoL (DAFNE Study Group, 2002; Speight et al.,
2010).
Although there is some controversy regarding the association
between HRQoL and insulin pump treatment (Barnard et al.,
2007) our results suggest that patients receiving this therapy
reported higher scores on Self-care and lower scores on
Interference; that is, they experience fewer limitations due to
their diabetes. Other studies have also found higher HRQoL in
people with this form of insulin administration (Nuboer et al.,
2008; Ortiz et al., 2010).
Patients with chronic complications scored lower on theWell-
being subscale. Other authors have already reported that chronic
complications decrease HRQoL in patients with type 1 diabetes
(Hahl et al., 2002; Jacobson et al., 2013).
ViDa1 also contributed information regarding other
subgroups of interest. Adolescents presented higher scores on
Well-being and lower scores on Worry, in accordance with
previous results (Millán et al., 2002). Women had lower scores
on Well-being and higher scores on Worry than men. Other
authors using the DQOL reported a greater impact and higher
degree of worry regarding diabetes among women (Millán et al.,
2002).
As for the temporal stability of the ViDa1 questionnaire, the
high correlations found in the retest suggest that it has good
test-retest reliability. The questionnaire also demonstrated its
sensitivity to change on the Self-care (t = 4.3; p < 0.001) and
Interference subscales (t = 1.9; p = 0.054) after an educational
program that promoted a flexible diet or after switching to a new
insulin treatment.
Among the main strengths of this study is the participation
of the patients themselves in delimiting the concept of HRQoL
and in developing the questionnaire, and the assessment of its
psychometric properties in a heterogeneous sample of patients
from many different regions of Spain. However, we are aware
that the study also has limitations. Firstly, HRQoL is a complex
construct, which is particularly difficult to measure. In the
second place, for PCA, we used orthogonal rotation. We are
aware that most phenomena assessed in health studies are
interrelated, and that perfect othogonality is difficult to find. The
correlations found between the factors obtained were relatively
low and the solution obtained with othogonal rotation was simple
informative and clinically applicable. In addition, only a small
sample of patients (N = 46) and three types of intervention were
used to measure sensitivity to change. One way of providing
more evidence regarding the questionnaire’s sensitivity to change
would be to carry out a longitudinal follow-up that records
several measures over time. Additional information could also be
provided by a specific study in adolescents, since only 52 subjects
were aged between 14 and 17 years. Finally, the questionnaire is in
Spanish; although this is the second most spoken language in the
world, a large number of patients will be unable to complete it at
present. In the future we hope to be able to make adaptations and
validations of the instrument in other languages so as to extend
its use.
CONCLUSION
The ViDa1 questionnaire is a new instrument for measuring
HRQoL in people with type 1 diabetes. It covers the
most important aspects of what it means to live with
this disease through its four dimensions: Interference of
diabetes in life, Self-care, Well-being, and Worry about the
disease.
Our results suggest that the ViDa1 questionnaire has adequate
psychometric properties and may be a useful tool for evaluating
the fluctuations in the disease that patients experience over their
lifetime, as well as for measuring the impact of specific education
programs.
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